Corona Remedies Share Price

1,941.1026.20 (1.37%)

Live
As On: 24 Jun, 2026, 01:56 PM IST
As On: 24 Jun, 2026, 01:56 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	1,930.00
High	2,023.00
Low	1,923.60
Prev Close	1,914.90
Volume	1,57,570
VWAP(₹)	1,984.16

Share Price	Value
Today/Current/Last	1,941.101,949.45
Previous Day	1,914.901,914.05

Corona Remedies Share Recommendations

Mean recosCurrent

STRONG BUY

2 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	1	1	1	1
Buy	1	1	1	1
Hold	-	-	-	-
Sell	-	-	-	-
Strong Sell	-	-	-	-
# Analysts	2	2	2	2

View all Stock Recommendations

News & Analysis

Stocks in news: IFCI, Tata Motors, General Insurance Corp, Corona Remedies, HFCL
News
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Announcements
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Announcements
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Announcements

View all Corona Remedies Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	357.20	344.66	363.40	348.56	295.11
Total Income Growth (%)	3.64	-5.16	4.26	18.11	-1.12
Total Expenses	301.08	287.81	291.86	285.68	249.51
Total Expenses Growth (%)	4.61	-1.39	2.16	14.50	4.85
EBIT	56.12	56.85	71.54	62.88	45.60
EBIT Growth (%)	-1.28	-20.53	13.78	37.89	-24.62
Profit after Tax (PAT)	45.33	41.27	52.32	46.20	31.55
PAT Growth (%)	9.84	-21.12	13.26	46.42	-29.81
EBIT Margin (%)	15.71	16.49	19.69	18.04	15.45
Net Profit Margin (%)	12.69	11.97	14.40	13.25	10.69
Basic EPS (₹)	7.41	6.75	8.55	7.55	5.16

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	357.20	344.66	363.40	348.56	295.11
Total Income Growth (%)	3.64	-5.16	4.26	18.11	-1.12
Total Expenses	301.36	287.81	291.86	285.68	249.51
Total Expenses Growth (%)	4.71	-1.39	2.16	14.50	4.85
EBIT	55.84	56.85	71.54	62.88	45.60
EBIT Growth (%)	-1.78	-20.53	13.77	37.89	-24.62
Profit after Tax (PAT)	45.05	41.25	52.15	46.40	31.34
PAT Growth (%)	9.21	-20.90	12.39	48.05	-30.00
EBIT Margin (%)	15.63	16.49	19.69	18.04	15.45
Net Profit Margin (%)	12.61	11.97	14.35	13.31	10.62
Basic EPS (₹)	7.37	6.74	8.53	7.59	5.12

	FY 2026	FY 2025	FY 2024
Total Revenue	1,413.83	1,202.35	1,020.93
Total Revenue Growth (%)	17.59	17.77	14.57
Total Expenses	1,154.58	1,004.21	902.46
Total Expenses Growth (%)	14.97	11.27	15.63
Profit after Tax (PAT)	185.12	149.43	90.50
PAT Growth (%)	23.88	65.11	6.56
Operating Profit Margin (%)	18.97	17.44	13.10
Net Profit Margin (%)	13.19	12.49	8.92
Basic EPS (₹)	30.27	24.43	14.80

	FY 2026	FY 2025
Total Revenue	1,413.83	1,202.35
Total Revenue Growth (%)	17.59	17.77
Total Expenses	1,154.58	1,004.21
Total Expenses Growth (%)	14.97	11.27
Profit after Tax (PAT)	184.85	149.05
PAT Growth (%)	24.02	64.70
Operating Profit Margin (%)	18.97	17.44
Net Profit Margin (%)	13.17	12.45
Basic EPS (₹)	30.22	24.37

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 28.72% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024
Total Assets	1,205.14	929.86	830.58
Total Assets Growth (%)	29.60	11.95	39.59
Total Liabilities	458.28	323.52	350.17
Total Liabilities Growth (%)	41.66	-7.61	87.75
Total Equity	746.86	606.34	480.41
Total Equity Growth (%)	23.17	26.21	17.60
Current Ratio (x)	0.96	1.41	1.29
Total Debt to Equity (x)	0.19	0.10	0.28
Contingent Liabilities	43.60	40.12	43.84

Annual	FY 2026	FY 2025
Total Assets	1,204.25	929.24
Total Assets Growth (%)	29.60	11.91
Total Liabilities	458.28	323.51
Total Liabilities Growth (%)	41.66	-7.61
Total Equity	745.97	605.73
Total Equity Growth (%)	23.15	26.15
Current Ratio (x)	0.96	1.41
Total Debt to Equity (x)	0.19	0.10
Contingent Liabilities	43.60	40.12

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024
Net Cash flow from Operating Activities	229.48	190.50	156.76
Net Cash used in Investing Activities	-256.15	-83.84	-266.64
Net Cash flow from Financing Activities	25.28	-106.59	98.55
Net Cash Flow	-1.39	0.07	-11.34
Closing Cash & Cash Equivalent	1.83	3.22	3.16
Closing Cash & Cash Equivalent Growth (%)	-43.22	2.12	-78.23
Total Debt/ CFO (x)	0.62	0.33	0.86

Annual	FY 2026	FY 2025
Net Cash flow from Operating Activities	229.48	190.49
Net Cash used in Investing Activities	-256.15	-83.84
Net Cash flow from Financing Activities	25.28	-106.59
Net Cash Flow	-1.39	0.07
Closing Cash & Cash Equivalent	1.83	3.22
Closing Cash & Cash Equivalent Growth (%)	-43.22	2.12
Total Debt/ CFO (x)	0.62	0.33

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 256.15 cr for investing activities which is an YoY increase of 205.52%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024
Return on Equity (%)	24.78	24.64	18.83
Return on Capital Employed (%)	31.54	30.24	21.91
Return on Assets (%)	15.36	16.07	10.89
Interest Coverage Ratio (x)	43.63	23.19	11.17
Asset Turnover Ratio (x)	1.31	1.36	1.42
Price to Earnings (x)	51.55	-	-
Price to Book (x)	12.74	-	-
EV/EBITDA (x)	31.62	-	-
EBITDA Margin (%)	21.67	20.55	15.88

Annual	FY 2026	FY 2025
Return on Equity (%)	24.77	24.60
Return on Capital Employed (%)	31.57	30.26
Return on Assets (%)	15.34	16.03
Interest Coverage Ratio (x)	43.63	23.19
Asset Turnover Ratio (x)	1.32	1.36
Price to Earnings (x)	51.55	-
Price to Book (x)	12.76	-
EV/EBITDA (x)	31.62	-
EBITDA Margin (%)	21.67	20.55

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Corona Remedies Ltd.	64.39	15.96	24.78	31.54	15.36	16.45	18.97	13.19	30.27	0.96	0.19	0.62
Glenmark Life	24.37	4.13	16.94	22.51	14.17	5.99	30.65	22.12	45.99	5.21	0.00	0.00
Concord Biotech Ltd.	51.88	6.72	12.93	16.71	11.67	7.53	32.73	24.29	24.78	7.39	0.00	0.00
Indegene	31.64	4.04	12.77	15.97	8.68	14.70	16.08	11.42	16.72	2.41	0.00	0.00
Marksans Pharma	28.63	3.92	13.82	17.53	10.82	16.46	19.81	14.23	9.22	5.17	0.01	0.06
Add More

Annual Ratios (%)

Choose from Peers

Sequent Scientific
Shilpa Medicare
Strides Shasun
Akums Drugs & Pharmaceuticals Ltd.
Sudeep Pharma Ltd.

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Corona Remedies Ltd. Stock Performance	1.49	8.81	20.51	27.50	0.00	0.00	0.00
Glenmark Life Stock Performance	0.19	5.35	4.46	23.06	1.79	112.96	0.00
Concord Biotech Ltd. Stock Performance	-1.74	13.60	24.08	17.95	-14.24	0.00	0.00
Indegene Stock Performance	-1.04	1.90	7.87	8.36	-12.46	0.00	0.00
Marksans Pharma Stock Performance	-0.60	30.94	49.57	48.22	5.67	252.52	253.94
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	4,21,97,968	69.00 %	0.00
Pledge	0	0.00 %	0.00
FII	13,73,973	2.25 %	0.40
DII	42,91,408	7.02 %	0.25
MF	38,82,091	6.35 %	-0.03
Others	1,32,96,739	21.73 %	-0.65

Category	Mar 2026	Dec 2025
Promoters	69.00	69.00
Pledge	0.00	0.00
FII	2.25	1.84
DII	7.02	6.77
Mutual Funds	6.35	6.38
Others	21.73	22.39

Mutual Funds Ownership

MF Ownership as on 31 May 2026

Invesco India Smallcap Direct-G
Equity: Small Cap
5
- 234.79
  Amount Invested (in Cr.)
- 2%
  % of AUM
- 0.00
  % Change (MoM basis)
Invesco India Mid Cap Direct-G
Equity: Mid Cap
4
- 117.37
  Amount Invested (in Cr.)
- 0.95%
  % of AUM
- 0.00
  % Change (MoM basis)
Invesco India Multicap Direct-G
Equity: Multi Cap
2
- 46.84
  Amount Invested (in Cr.)
- 1.15%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
Final
100%
May 11, 2026
Board Meeting
Audited Results & Final Dividend
Apr 30, 2026
Board Meeting
Quarterly Results
Jan 27, 2026
Board Meetings
Announced on Meeting on
Apr 30, 2026 May 11, 2026
Audited Results & Final Dividend
Jan 27, 2026 Feb 02, 2026
Quarterly Results
Dec 26, 2025 Jan 02, 2026
Quarterly Results
Dividends
Announced on Ex-Date Dividend%
May 11, 2026 Jun 19, 2026 100%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
No Data Available

Announced on	Meeting on
Apr 30, 2026	May 11, 2026
Audited Results & Final Dividend
Jan 27, 2026	Feb 02, 2026
Quarterly Results
Dec 26, 2025	Jan 02, 2026
Quarterly Results

Announced on	Ex-Date	Dividend%
May 11, 2026	Jun 19, 2026	100%

About Corona Remedies

Corona Remedies Ltd., incorporated in the year 2004, is a Small Cap company (having a market cap of Rs 11,711.55 Crore) operating in Pharmaceuticals sector.

Corona Remedies Ltd. key Products/Revenue Segments include Pharmaceutical Products, Sale of services, Export Incentives, Other Operating Revenue and Scrap for the year ending 31-Mar-2026.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 357.20 Crore, up 3.64 % from last quarter Total Income of Rs 344.66 Crore and up 21.04 % from last year same quarter Total Income of Rs 295.11 Crore. Company has reported net profit after tax of Rs 45.33 Crore in latest quarter.

The company’s top management includes Dr.Kirtikumar Mehta, Mr.Nirav Mehta, Mr.Ankur Mehta, Mr.Viral Sitwala, Mr.Ameet Desai, Mr.Bhaskar Iyer, Ms.Monica Kanuga, Mr.Shirish Belapure, Mr.Bhavin Bhagat, Ms.Chetna Dharajiya. Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-03-2026, the company has a total of 6.12 Crore shares outstanding.

Corona Remedies Share Price Today is Rs. 1941.10. On previous day, the Corona Remedies Share Price (NSE) closed at Rs. 1846.7, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 69.0% of the stake in Corona Remedies shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Corona Remedies stocks was 2.25% as compared to 1.84% in Dec 2025 with increase of 0.41%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 7.02% as compared to 6.77% in Dec 2025 with increase of 0.25%. Out of the total DII holdings in Corona Remedies shares 6.35% was held by mutual funds. The rest including public held is 21.73%. Corona Remedies stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Corona Remedies Dividend: Ever since 2004, Corona Remedies dividends has been paid out around 1 times. As on 24 Jun, 2026, 01:56 PM IST, The overall dividend yield for Corona Remedies stands at 0.52%. The last dividend paid was on June 19, 2026 (Rs. 10.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 30.27.

Corona Remedies Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 357.2 Cr. of sales and 0.0% of quarterly net null, there have been multiple ups and downs in the Corona Remedies stock prices in the past few weeks. For example, Corona Remedies stock price on 16th of June 2026 was around Rs. 1750.6. Corona Remedies share price now stands at an average of Rs. 1941.10. Judging by last week's performance, stock is in up trend.

Corona Remedies has a median target price of Rs. 1948.5 in 12 months by 2 analysts. They have provided a high estimate of Rs. 2047.0 and low estimate of Rs. 1850.0 for Corona Remedies share.

Historical Prices and Performance:
Corona Remedies, incorporated in 2004 is a Mid Cap company (with a market cap of Rs. 11711.55) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Corona Remedies stock was 24.78%, 24.64%, 18.83%, 20.78% and 0.0% respectively.
The Corona Remedies share gave a 3 year return of 0.0% as compared to Nifty 50 which gave a return of 0.0%.
Corona Remedies announced 100.0% final dividend on June 19, 2026.

Key Metrics:
PE Ratio of Corona Remedies is 63.27
Prices/Sales Ratio of Corona Remedies is 6.78
Price/Book Ratio of Corona Remedies is 15.68

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Corona Remedies, major competitors and peers include Concord Biotech Ltd., Glenmark Life, Indegene and Marksans Pharma. As of Dec 2025, the dividend yield of Corona Remedies stands at 0.52% while Concord Biotech Ltd., Glenmark Life, Indegene and Marksans Pharma stand at 0.0%, 0.0%, 0.0% and 0.34% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 63.27 and 15.68 respectively.

Leadership of Corona Remedies :
Chetna Dharajiya is Co. Secretary & Compl. Officer
Bhavin Bhagat is Chief Financial Officer
Kirtikumar Mehta is Chairman & Non-Exe.Director
Nirav Mehta is Managing Director & CEO
Ankur Mehta is Joint Managing Director
Viral Sitwala is Whole Time Director
Ameet Desai is Independent Director
Monica Kanuga is Independent Director
Shirish Belapure is Independent Director
Bhaskar Iyer is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

BSE Healthcare, BSE IPO Index, BSE AllCap, BSE NEXT 500, Nifty IPO

Address

CORONA House,C Mondeal Business Park,Near Gurudwara,Ahmedabad, Gujarat - 380059

Contact

investor@coronaremedies.com

http://www.coronaremedies.com

PE Ratio(x)	64.27
EPS - TTM(₹)	30.27
MCap(₹ Cr.)	11,953.74
MCap Rank	43
PB Ratio(x)	16.33
Div Yield(%)	0.51
Face Value(₹)	10.00
52W High(₹)	2,100.70
52W Low(₹)	1,336.60
MCap/Sales	6.78
Beta(1 Month)	-
BV/Share(₹)	122.12

PE Ratio(x)	64.41
EPS - TTM(₹)	30.27
MCap(₹ Cr.)	11,934.47
MCap Rank	43
PB Ratio(x)	15.57
Div Yield(%)	0.51
Face Value(₹)	10.00
52W High(₹)	2,097.35
52W Low(₹)	1,336.95
MCap/Sales	6.78
Beta(1 Month)	-
BV/Share(₹)	122.12

1 Day	1.37%
1 Month	15.23%
3 Months	23.42%
1 Year	N.A.
3 Years	N.A.
5 Years	N.A.

1 Day	1.84%
1 Month	15.88%
3 Months	23.95%
1 Year	N.A.
3 Years	N.A.
5 Years	N.A.

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Corona Remedies Share Price

Key Metrics